Castle Biosciences has signed an agreement to acquire GI health company Previse, which was developed by specialists at Johns Hopkins University School of Medicine in Baltimore. Previse is focused on chronic acid reflux related diseases, including esophageal cancer, according to a May 5 news release from Castle Biosciences. Terms of the agreement have not been […]
The post Castle Biosciences to acquire Johns Hopkins-backed GI company appeared first on Becker’s ASC.